Growth hormone (GH) activity is associated with increased serum oestradiol and reduced anti-Müllerian hormone in healthy male volunteers treated with GH and a GH antagonist.

Andreassen M, Frystyk J, Faber J, Kristensen LØ, Juul A

Andrology1 Jul 2013Cited by 16 (Europe PMC)

PMID23785020DOI10.1111/j.2047-2927.2013.00096.xPepBankPUB-23785020

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In healthy men, pegvisomant reduced IGF-I from 204 (160-290) to 106 (97-157) μg/L (p = 0.001).
In plain wordsIn healthy men, pegvisomant reduced IGF-I compared with before treatment.
Peptide
Pegvisomant
Outcome
DecreaseIGF-I
Study
n = 8
Comparator
Before pegvisomant treatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 mg/day first week, 15 mg/day last 2 weeks · 3 weeksAs given in this study (human).
Measurements
IGF-I median
204 μg/L
before pegvisomant treatment
IGF-I interquartile range
160 to 290 μg/L
before pegvisomant treatment
IGF-I median
106 μg/L
during pegvisomant treatment
IGF-I interquartile range
97 to 157 μg/L
during pegvisomant treatment
Source sentences
Summary
During pegvisomant treatment IGF-I (204 (160-290) vs. 106 (97-157) μg/L, p = 0.001) and oestradiol (86 ± 28 vs. 79 ± 25 pm, p = 0.060) decreased.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight healthy male volunteers (mean age 35, range 29-46 years) were treated with GH for 3 weeks (1st week 0.01, 2nd week 0.02, 3rd week 0.03 mg/day/kg) or a GH receptor antagonist (Pegvisomant) (1st week 10, last 2 weeks 15 mg/day), separated by 8 weeks of washout.
Report a problemFND-2378502001
02HumanNon-randomized trialEfficacy outcome
In healthy men, oestradiol decreased from 86 ± 28 to 79 ± 25 pm during pegvisomant treatment (p = 0.060).
In plain wordsIn healthy men, oestradiol decreased during pegvisomant treatment compared with before treatment, with p = 0.060.
Peptide
Pegvisomant
Outcome
DecreaseOestradiol
Study
n = 8
Comparator
Before pegvisomant treatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
10 mg/day first week, 15 mg/day last 2 weeks · 3 weeksAs given in this study (human).
Measurements
Oestradiol mean
86 pm
before pegvisomant treatment
Oestradiol standard deviation
28 pm
before pegvisomant treatment
Oestradiol mean
79 pm
during pegvisomant treatment
Oestradiol standard deviation
25 pm
during pegvisomant treatment
Source sentences
Summary
During pegvisomant treatment IGF-I (204 (160-290) vs. 106 (97-157) μg/L, p = 0.001) and oestradiol (86 ± 28 vs. 79 ± 25 pm, p = 0.060) decreased.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight healthy male volunteers (mean age 35, range 29-46 years) were treated with GH for 3 weeks (1st week 0.01, 2nd week 0.02, 3rd week 0.03 mg/day/kg) or a GH receptor antagonist (Pegvisomant) (1st week 10, last 2 weeks 15 mg/day), separated by 8 weeks of washout.
Report a problemFND-2378502002
03HumanNon-randomized trialEfficacy outcome
In healthy men, other reproductive hormones showed no significant changes or trends during pegvisomant treatment.
In plain wordsIn healthy men, other reproductive hormones showed no significant changes or trends with pegvisomant compared with before treatment.
Peptide
Pegvisomant
Outcome
No significant changeOther reproductive hormones
Study
n = 8
Comparator
Before pegvisomant treatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
10 mg/day first week, 15 mg/day last 2 weeks · 3 weeksAs given in this study (human).
Source sentences
Summary
No significant changes or trends in the other reproductive hormones occurred during the two treatment regimens.
2 context sentences(design, population, supporting numbers)
Summary · context
Before and after the two treatment periods, concentrations of luteinizing hormone (LH), follicle-stimulating hormone, testosterone, oestradiol, sex hormone-binding globulin, inhibin B and Anti-Müllerian Hormone (AMH) were measured.
Summary · context
Eight healthy male volunteers (mean age 35, range 29-46 years) were treated with GH for 3 weeks (1st week 0.01, 2nd week 0.02, 3rd week 0.03 mg/day/kg) or a GH receptor antagonist (Pegvisomant) (1st week 10, last 2 weeks 15 mg/day), separated by 8 weeks of washout.
Report a problemFND-2378502003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT00969644

The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons

Herlev Hospitaln = 12Sept 2009 to est. Mar 2010

Interaction Between the GH/IGF-I System and the Immune-system

Trial page ClinicalTrials.govUpdated 1 Sept 2009

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.